Atsushi Hirano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Atsushi Hirano has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Junji Umeno
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications- Motohiro Esaki
Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Saga University Saga Japan
2 shared publications Shin Fujioka
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publicationsTakanari Kitazono
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications- Takehiro Torisu
Department of Medicine and Clinical Science, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan
2 shared publications Tomohiko Moriyama
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications
Latest Publications
- Open Access
- 30 April 2022
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 20 (2) , 260-268
One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study
Background/Aims: Recent studies suggested a favorable effect of indigo naturalis (IN) in inducing remission for refractory ulcerative colitis (UC), however, the maintenance effect of IN for patients with UC remains unknown. Therefore, we conducted a prospective uncontrolled open-label study to analyze the efficacy and safety of IN for patients with UC.Methods: Patients with moderate to severe active UC (clinical activity index [CAI] ≥ 8) took 2 g/day of IN for 52 weeks. CAI at weeks 0, 4, 8, and 52 and Mayo endoscopic subscore (MES) and Geboes score (GS) at weeks 0, 4, and 52 were assessed. Clinical remission (CAI ≤ 4), mucosal healing (MES ≤ 1), and histological healing (GS ≤ 1) rates at each assessment were evaluated. Overall adverse events (AEs) during study period were also evaluated. The impact of IN on mucosal microbial composition was assessed using 16S ribosomal RNA gene sequences.Results: Thirty-three patients were enrolled. The rates of clinical remission at weeks 4, 8, and 52 were 67%, 76%, and 73%, respectively. The rates of mucosal healing at weeks 4 and 52 were 48% and 70%, respectively. AEs occurred in 17 patients (51.5%) during follow-up. Four patients (12.1%) showed severe AEs, among whom 3 manifested acute colitis. No significant alteration in the mucosal microbial composition was observed with IN treatment.Conclusions: One-year treatment of moderate to severe UC with IN was effective. IN might be a promising therapeutic option for maintaining remission in UC, although the relatively high rate of AEs should be considered.
- 30 April 2022
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 20 (2) , 260-268
Open AccessOne-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study
Background/Aims: Recent studies suggested a favorable effect of indigo naturalis (IN) in inducing remission for refractory ulcerative colitis (UC), however, the maintenance effect of IN for patients with UC remains unknown. Therefore, we conducted a prospective uncontrolled open-label study to analyze the efficacy and safety of IN for patients with UC.Methods: Patients with moderate to severe active UC (clinical activity index [CAI] ≥ 8) took 2 g/day of IN for 52 weeks. CAI at weeks 0, 4, 8, and 52 and Mayo endoscopic subscore (MES) and Geboes score (GS) at weeks 0, 4, and 52 were assessed. Clinical remission (CAI ≤ 4), mucosal healing (MES ≤ 1), and histological healing (GS ≤ 1) rates at each assessment were evaluated. Overall adverse events (AEs) during study period were also evaluated. The impact of IN on mucosal microbial composition was assessed using 16S ribosomal RNA gene sequences.Results: Thirty-three patients were enrolled. The rates of clinical remission at weeks 4, 8, and 52 were 67%, 76%, and 73%, respectively. The rates of mucosal healing at weeks 4 and 52 were 48% and 70%, respectively. AEs occurred in 17 patients (51.5%) during follow-up. Four patients (12.1%) showed severe AEs, among whom 3 manifested acute colitis. No significant alteration in the mucosal microbial composition was observed with IN treatment.Conclusions: One-year treatment of moderate to severe UC with IN was effective. IN might be a promising therapeutic option for maintaining remission in UC, although the relatively high rate of AEs should be considered.
- 7 August 2019
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 35 (3) , 412-417
Short‐term and long‐term outcomes of indigo naturalis treatment for inflammatory bowel disease
Background and Aim: Indigo naturalis (IN) is a traditional Chinese herbal medicine reported to be effective in inducing remission in ulcerative colitis (UC). We conducted a retrospective observational study to investigate the efficacy and safety of IN for induction and maintenance therapy in patients with inflammatory bowel disease.Methods: Data were collected from the electric medical records of patients with inflammatory bowel disease who had started IN treatment between March 2015 and April 2017 at Kyushu University Hospital. Clinical response and remission rates were assessed based on the clinical activity index determined by Rachmilewitz index or Crohn's disease (CD) activity index. Cumulative IN continuation rates were estimated using the Kaplan–Meier method. Overall adverse events (AEs) during follow‐up were also analyzed.Results: Seventeen UC patients and eight CD patients were enrolled. Clinical response and remission rates at week 8 were 94.1% and 88.2% in UC patients and 37.5% and 25.0% in CD patients, respectively. Clinical remission rates, as assessed through non‐responders imputation analyses at weeks 52 and 104, were 76.4% and 70.4% in UC patients and 25.0% and 25.0% in CD patients, respectively. Ten patients (40%) experienced AEs during follow‐up. Three patients (12%) experienced severe AEs, including acute colitis requiring hospitalization in two patients and acute colitis with intussusception requiring surgery in one patient.Conclusions: Indigo naturalis showed favorable therapeutic efficacy in UC, whereas its therapeutic efficacy in CD appeared to be modest. The risk of severe AEs should be recognized for IN treatment.
- 7 August 2019
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 35 (3) , 412-417
Short‐term and long‐term outcomes of indigo naturalis treatment for inflammatory bowel disease
Background and Aim: Indigo naturalis (IN) is a traditional Chinese herbal medicine reported to be effective in inducing remission in ulcerative colitis (UC). We conducted a retrospective observational study to investigate the efficacy and safety of IN for induction and maintenance therapy in patients with inflammatory bowel disease.Methods: Data were collected from the electric medical records of patients with inflammatory bowel disease who had started IN treatment between March 2015 and April 2017 at Kyushu University Hospital. Clinical response and remission rates were assessed based on the clinical activity index determined by Rachmilewitz index or Crohn's disease (CD) activity index. Cumulative IN continuation rates were estimated using the Kaplan–Meier method. Overall adverse events (AEs) during follow‐up were also analyzed.Results: Seventeen UC patients and eight CD patients were enrolled. Clinical response and remission rates at week 8 were 94.1% and 88.2% in UC patients and 37.5% and 25.0% in CD patients, respectively. Clinical remission rates, as assessed through non‐responders imputation analyses at weeks 52 and 104, were 76.4% and 70.4% in UC patients and 25.0% and 25.0% in CD patients, respectively. Ten patients (40%) experienced AEs during follow‐up. Three patients (12%) experienced severe AEs, including acute colitis requiring hospitalization in two patients and acute colitis with intussusception requiring surgery in one patient.Conclusions: Indigo naturalis showed favorable therapeutic efficacy in UC, whereas its therapeutic efficacy in CD appeared to be modest. The risk of severe AEs should be recognized for IN treatment.
- Open Access
- 22 May 2019
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (10) , 1671
Gastrointestinal: A case of zonisamide‐induced esophageal and small intestinal injury
- 22 May 2019
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 34 (10) , 1671
Open AccessGastrointestinal: A case of zonisamide‐induced esophageal and small intestinal injury
- 20 February 2018
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 33 (9) , 1590-1597
Comparison of the microbial community structure between inflamed and non‐inflamed sites in patients with ulcerative colitis
Background and Aim: The gut microbiota is suggested to play an important role in the pathogenesis of ulcerative colitis (UC). However, interindividual and spatial variations hamper the identification of UC‐related changes. We thus investigated paired mucosa‐associated microbiota obtained from both inflamed and non‐inflamed sites of UC patients and corresponding sites of non‐inflammatory bowel disease (IBD) controls.Methods: Mucosal biopsies of both inflamed and non‐inflamed sites were obtained from 14 patients with active UC of the left‐sided or proctitis type. Paired mucosal biopsies of the corresponding sites were obtained from 14 non‐IBD controls. The microbial community structure was investigated using 16S ribosomal RNA gene sequences, followed by data analysis using qiime and LEfSe softwares.Results: Microbial alpha diversity in both inflamed and non‐inflamed sites was significantly lower in UC patients compared with non‐IBD controls. There were more microbes of the genus Cloacibacterium and the Tissierellaceae family, and there were less microbes of the genus Neisseria at the inflamed site when compared with the non‐inflamed site in UC patients. Decreased abundance of the genera Prevotella, Eubacterium, Neisseria, Leptotrichia, Bilophila, Desulfovibrio, and Butyricimonas was evident at the inflamed site of UC patients compared with the corresponding site of non‐IBD controls. Among these taxa, the genera Prevotella and Butyricimonas were also less abundant at the non‐inflamed site of UC patients compared with the corresponding site in non‐IBD controls.Conclusions: Mucosal microbial dysbiosis occurs at both inflamed and non‐inflamed sites in UC patients. The taxa showing altered abundance in UC patients might mediate colonic inflammation.
- 20 February 2018
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 33 (9) , 1590-1597
Comparison of the microbial community structure between inflamed and non‐inflamed sites in patients with ulcerative colitis
Background and Aim: The gut microbiota is suggested to play an important role in the pathogenesis of ulcerative colitis (UC). However, interindividual and spatial variations hamper the identification of UC‐related changes. We thus investigated paired mucosa‐associated microbiota obtained from both inflamed and non‐inflamed sites of UC patients and corresponding sites of non‐inflammatory bowel disease (IBD) controls.Methods: Mucosal biopsies of both inflamed and non‐inflamed sites were obtained from 14 patients with active UC of the left‐sided or proctitis type. Paired mucosal biopsies of the corresponding sites were obtained from 14 non‐IBD controls. The microbial community structure was investigated using 16S ribosomal RNA gene sequences, followed by data analysis using qiime and LEfSe softwares.Results: Microbial alpha diversity in both inflamed and non‐inflamed sites was significantly lower in UC patients compared with non‐IBD controls. There were more microbes of the genus Cloacibacterium and the Tissierellaceae family, and there were less microbes of the genus Neisseria at the inflamed site when compared with the non‐inflamed site in UC patients. Decreased abundance of the genera Prevotella, Eubacterium, Neisseria, Leptotrichia, Bilophila, Desulfovibrio, and Butyricimonas was evident at the inflamed site of UC patients compared with the corresponding site of non‐IBD controls. Among these taxa, the genera Prevotella and Butyricimonas were also less abundant at the non‐inflamed site of UC patients compared with the corresponding site in non‐IBD controls.Conclusions: Mucosal microbial dysbiosis occurs at both inflamed and non‐inflamed sites in UC patients. The taxa showing altered abundance in UC patients might mediate colonic inflammation.
- 26 March 2007
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 7 (1) , 83-88
Successful treatment of idiopathic thrombocytopenic purpura by Chinese herbal medicine EK‐49 and ascorbic acid in an elderly patient developing chronic subdural hematoma
Treatment of idiopathic thrombocytopenic purpura can present difficult therapeutic choices. An 88‐year‐old woman was admitted for treatment of a right subdural hematoma. She had a history of chronic thrombocytopenia, with follow‐up evaluations by a local physician. Platelet count on admission was 5 × 103/µL, with a high serum concentration of platelet‐associated immunoglobulin G. Bone marrow examination showed a marked increase in megakaryocytes. The patient was diagnosed with idiopathic thrombocytopenic purpura accompanied by chronic subdural hematoma. An increase in platelet count and gradual resolution of the subdural hematoma were obtained with prednisolone and azathioprine administration, but platelet count decreased when steroid tapering was attempted. Ultimately we administered the Chinese herbal medicine EK‐49 and ascorbic acid, with a gradual increase in platelet count and no adverse effects. Some elderly patients with chronic subdural hematoma can be treated non‐invasively. Further, a combination of EK‐49 and ascorbic acid may be an effective treatment for refractory idiopathic thrombocytopenic purpura.
- 26 March 2007
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 7 (1) , 83-88
Successful treatment of idiopathic thrombocytopenic purpura by Chinese herbal medicine EK‐49 and ascorbic acid in an elderly patient developing chronic subdural hematoma
Treatment of idiopathic thrombocytopenic purpura can present difficult therapeutic choices. An 88‐year‐old woman was admitted for treatment of a right subdural hematoma. She had a history of chronic thrombocytopenia, with follow‐up evaluations by a local physician. Platelet count on admission was 5 × 103/µL, with a high serum concentration of platelet‐associated immunoglobulin G. Bone marrow examination showed a marked increase in megakaryocytes. The patient was diagnosed with idiopathic thrombocytopenic purpura accompanied by chronic subdural hematoma. An increase in platelet count and gradual resolution of the subdural hematoma were obtained with prednisolone and azathioprine administration, but platelet count decreased when steroid tapering was attempted. Ultimately we administered the Chinese herbal medicine EK‐49 and ascorbic acid, with a gradual increase in platelet count and no adverse effects. Some elderly patients with chronic subdural hematoma can be treated non‐invasively. Further, a combination of EK‐49 and ascorbic acid may be an effective treatment for refractory idiopathic thrombocytopenic purpura.
- 1 August 1994
- Published by Springer Nature in Acta Neuropathologica
- Vol. 88 (2) , 180-184
Demonstration of neurofibrillary tangles and neuropil thread-like structures in spinal cord white matter in parkinsonism-dementia complex on Guam and in Guamanian amyotrophic lateral sclerosis
This report concerns the demonstration and distribution of neurofibrillary tangles (NFTs), immunoreactive neuropil thread-like structures and dots in the spinal cord gray and white matter of six patients with parkinsonism-dementia complex on Guam and five patients with Guamanian amyotrophic lateral sclerosis (ALS). A monoclonal antibody to Alzheimer NFTs was used. NFTs were found in the spinal cord gray matter and white matter and all patients had immunoreactive neuropil thread-like structures and dots in the gray matter as well as in the white matter. They were particularly numerous in the lateral funiculus of patients with Guamanian ALS.
- 1 August 1994
- Published by Springer Nature in Acta Neuropathologica
- Vol. 88 (2) , 180-184
Demonstration of neurofibrillary tangles and neuropil thread-like structures in spinal cord white matter in parkinsonism-dementia complex on Guam and in Guamanian amyotrophic lateral sclerosis
This report concerns the demonstration and distribution of neurofibrillary tangles (NFTs), immunoreactive neuropil thread-like structures and dots in the spinal cord gray and white matter of six patients with parkinsonism-dementia complex on Guam and five patients with Guamanian amyotrophic lateral sclerosis (ALS). A monoclonal antibody to Alzheimer NFTs was used. NFTs were found in the spinal cord gray matter and white matter and all patients had immunoreactive neuropil thread-like structures and dots in the gray matter as well as in the white matter. They were particularly numerous in the lateral funiculus of patients with Guamanian ALS.